-
FDA approves Dermira's Qbrexza for treatment of primary armpit hyperhidm
Time of Update: 2020-06-11
primary armpit hyperhidm, often referred to as excessive underarm sweating, is a chronic skin disease that causes sweating to exceed the amount required for normal body temperature regulation The ex
-
Phase 2b study of diluted polyvicanone iodine in Veloce's new DMSO solvent system yielded positive results
Time of Update: 2020-06-11
yesterday (October 8), Veloce BioPharma, LLC ("Veloce")," announced positive results from its Phase 2 b study on dilution of polyvione iodine in the new DMSO solvent system, which is used for local
-
FDA approves Fulphila for non-bone marrow cancer patients undergoing bone marrow-inhibited chemotherapy
Time of Update: 2020-06-11
recently, the U.S FDA (approved Fulphila (pegfilgrastim-jmdb) for use in non-bone marrow cancer patients undergoing bone marrow inhibition chemotherapy to reduce the incidence of febrile neutropen
-
Merthyr's heavy anti-PD-1 cancer immunotherapy Keytruda Phase 3 clinical trial reaches major endpoint
Time of Update: 2020-06-11
Today, The of The of Mercadon (announced that the company's heavy-duty anti-PD-1 cancer immunotherapy Keytruda, as a second-line therapy, reached the primary end of the phase 3 clinical trial in
-
FDA approves for launch of Therapeutics MD's BIJUVA ™ capsule (1 mg/100 mg)
Time of Update: 2020-06-11
as the ovaries stop producing hormones and circulating estrogen levels drop, they often develop symptoms of tube aureus (VMS, also known as hot/tidal), as well as sleep and mood disorders and urinar
-
FDA approves Novartis' new oral targeted cancer drug Kisqali for treatment of patients with advanced or metastatic breast cancer
Time of Update: 2020-06-11
recently, Swiss Pharmaceutical scoundrel Novartis announced that the U.S Food and Drug ( FDA () has approved the new oral targeting anti-cancer drug Kisqali (ribociclib) for the treatment of pat
-
FDA accepts application for license to supplement biologics for Mercay's heavy immunotherapy Keytruda
Time of Update: 2020-06-11
recently, MSD announced that FDA (receiving a supplementary biologic license application (sBLA) for its heavy immunotherapy Keytruda (pembrolizumab) for complementary treatment (adjuvant therapy)
-
NICE recommends Pfizer Mylotarg in combination with chemotherapy to treat acute myeloid leukemia
Time of Update: 2020-06-11
recently, the National Health (nice) in the UK has decided to recommend Pfizer Mylotarg in combination with chemotherapy to treat previously untreated, cd33-positive acute myeloid leukemia about
-
BMS Announces Phase II ELOQUENT-3 Study Reaches Major End
Time of Update: 2020-06-11
recently, BMS announced at the EHA 2018 annual meeting that the second phase of the ELOQUENT-3 study reached its main endpoint, with empliciti (elotuzumab) combining pomaduamine and low-dose dexamet
-
New drug for the treatment of Alzheimer's disease, "Glucosaccharide Diacid (GV-971)" successfully completed clinical Phase 3 trial
Time of Update: 2020-06-11
Recently, the Shanghai Green Valley Pharmaceutical (Limited Company (announced by The University of China, the Chinese Academy of Sciences, Shanghai Pharmaceutical (Research Institute and Shan
-
Roche's new drug taselisib in combination with conventional hormone therapy could slow the growth of advanced breast cancer
Time of Update: 2020-06-11
recently, in a Phase 3 clinical trial , Roche's new drug (combined with conventional hormone therapy) could slow the growth of advanced breast cancer and reduce the risk of cancer deterioration
-
St. Baishi Squibb's clinical phase 2 trial on the treatment of plaque-like psoriasis patients in the new drug BMS-986165 reaches the main endpoint
Time of Update: 2020-06-11
September 13, the company's company, BMS, (announced that it is the treatment of psoriasis) in the research of new drug (in the treatment of patients with moderate to severe plaque psoriasis pat
-
FDA approves Inveltys for treatment of inflammation and pain after ophthalmology surgery
Time of Update: 2020-06-11
, Kala Pharma recently completed the announcement that the U.S Food and Drug ( FDA ()) has approved Inveltys (chloretteno leachate, 1%) for the treatment of inflammation and pain after ophthalmic
-
CHMP recommends approval of biosimilar Trazimera for treatment of stomach cancer or gastroesophageal coesophageal adenocarcinoma
Time of Update: 2020-06-11
, u.S Pharmaceuticals (PFizer) announced that the European Pharmaceutical (EMA) for Medicines (CHMP) has issued a positive opinion recommending the approval of biosimilar Trazimera for her2-pos
-
European Commission approves Sanofi nanoantibody drug Cablivi for treatment of adult patients with aTTP
Time of Update: 2020-06-11
aTTP is a life-threatening, autoimmune-based clotting disorder characterized by the formation of large numbers of blood clots in small blood vessels throughout the body, leading to severe thrombocyto
-
EC approves Keytruda joint Alimta first-line treatment of metastatic non-squamous non-small cell lung cancer adult patients
Time of Update: 2020-06-11
recently, the cancer immunotherapy giant Merck and Co announced that the European Commission (EC) has approved the PD-1 tumor immunotherapy Keytruda (pembrolizumab, Pablo bead monoantigen) combined
-
Cinda Biorecoa Whole Human Source Anti-CD47 monoclonal antibody body approved by FDA for drug clinical trial
Time of Update: 2020-06-11
recently, Cinda Bio announced that the Company (developed recombinant whole-human source anti-CD47 monoclonal antibody (research code: IBI-188), has been the United States Food Drug (the Drug
-
FDA approves CT-P10 for treatment of B-cell non-Hodgkin lymphoma
Time of Update: 2020-06-11
recently, Celltrion (and its partner, Teva Pharmaceutical Industries) announced that the U.S the FDA (The Oncology Drug (Consulting (the Committee recommended the FDA's approval of CT-P10 for
-
FDA approves Roche's avetin ® combined chemotherapy (caplatinum and yewalcohol) for treatment of patients with advanced ovarian cancer
Time of Update: 2020-06-11
recently, the Swiss Roche Group announced that the U.S FDA (approved an avetin ® (bevazumab) combined chemotherapy (caplatinum and yew alcohol) for the treatment of patients with advanced (III or
-
EC approves Fortescue Pharmaceuticals Symkevi in conjunction with Kalydeco for treatment of cystic fibrosis patients aged 12 and over
Time of Update: 2020-06-11
recently, the of the European Commission (EC) has approved Symkevi (tezacaftor/ivacaftor) in conjunction with Kalydeco (ivacaftor) for patients aged 12 and over with cystic fibrosis (CF) in additi
